Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Side Effects Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Full Prescribing Info

Indications/Uses

pms-ERLOTINIB is prescribed because of non-small cell lung cancer at an advanced stage and: chemotherapy has not helped to stop the disease; or the disease has not worsened after 4 cycles of first line chemotherapy; or a confirmed activating mutation of the Epidermal Growth Factor Receptor tyrosine kinase (EGFR-TK).
pms-ERLOTINIB is NOT indicated for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumours DO NOT HAVE an epidermal growth factor receptor (EGFR) activating mutation.

pms-Erlotinib Indications/Uses

erlotinib

Manufacturer:

Pharmascience

Distributor:

T-BOMA